Amoaku Winfried, Balaskas Konstantinos, Cudrnak Tomas, Downey Louise, Groppe Markus, Mahmood Sajjad, Mehta Hemal, Mohamed Quresh, Mushtaq Bushra, Severn Philip, Vardarinos Athanasios, Yang Yit, Younis Saad
Academic Ophthalmology, Division of Clinical Neuroscience, University of Nottingham, Nottingham, UK.
NIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and University College of London Institute of Ophthalmology, London, UK.
Clin Ophthalmol. 2018 Sep 10;12:1731-1740. doi: 10.2147/OPTH.S174560. eCollection 2018.
The treatment of neovascular (wet) age-related macular degeneration (AMD) with ranibizumab is now very well established in terms of efficacy and safety. Recent clinical trials and real-world studies have demonstrated the advantages of a Treat-and-Extend (T&E) regimen, and many hospital departments are now in the process of adopting this new regimen in favor of the pro re nata regimen for initiating and continuing ranibizumab therapy for patients with wet AMD. The comprehensive spectrum of issues related to implementation of the regimen is covered qualitatively in ten didactic topics provided by a group of clinicians with direct experience of this regimen in their department. The topics include definition, new and previously treated eyes, management of high-frequency injections, maximum extensions, discontinuing T&E, bilateral cases, clerical, audit, and patient counseling. This article aims to provide a useful resource for the implementation of the T&E regimen. A quantitative summary of the visual outcomes in key publications is also provided in this article. This article should be a valuable resource for staff training.
就疗效和安全性而言，雷珠单抗治疗新生血管性（湿性）年龄相关性黄斑变性（AMD）现已得到充分确立。近期的临床试验和真实世界研究已证明了“治疗并延长”（T&E）方案的优势，许多医院科室目前正采用这种新方案，而不是按需给药方案来启动和继续对湿性AMD患者使用雷珠单抗治疗。一组在其科室直接实施该方案的临床医生提供了十个教学主题，对与该方案实施相关的一系列综合问题进行了定性阐述。这些主题包括定义、初治眼和曾治眼、高频注射的管理、最大延长时间、停止T&E方案、双侧病例、文书工作、审核以及患者咨询。本文旨在为T&E方案的实施提供有用的参考资料。本文还提供了关键出版物中视觉结果的定量总结。本文对于员工培训应是一份有价值的参考资料。
